Free Trial

Viatris (VTRS) Competitors

Viatris logo
$10.30 -0.12 (-1.10%)
As of 10:21 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

VTRS vs. PFE, TAK, ARGX, ONC, BNTX, INSM, TEVA, SMMT, GMAB, and RDY

Should you be buying Viatris stock or one of its competitors? The main competitors of Viatris include Pfizer (PFE), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "medical" sector.

Viatris vs. Its Competitors

Pfizer (NYSE:PFE) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

68.4% of Pfizer shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Comparatively, 0.1% of Viatris shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$63.63B2.21$8.03B$1.8813.16
Viatris$14.74B0.82-$634.20M-$2.90-3.56

Pfizer has a net margin of 16.84% compared to Viatris' net margin of -24.57%. Pfizer's return on equity of 21.42% beat Viatris' return on equity.

Company Net Margins Return on Equity Return on Assets
Pfizer16.84% 21.42% 9.12%
Viatris -24.57%16.54%7.06%

In the previous week, Pfizer had 62 more articles in the media than Viatris. MarketBeat recorded 65 mentions for Pfizer and 3 mentions for Viatris. Pfizer's average media sentiment score of 1.15 beat Viatris' score of 0.55 indicating that Pfizer is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pfizer
47 Very Positive mention(s)
5 Positive mention(s)
9 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive
Viatris
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 7.0%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 4.7%. Pfizer pays out 91.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Viatris pays out -16.6% of its earnings in the form of a dividend. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Pfizer currently has a consensus price target of $28.12, suggesting a potential upside of 13.63%. Viatris has a consensus price target of $10.40, suggesting a potential upside of 0.82%. Given Pfizer's stronger consensus rating and higher possible upside, equities research analysts plainly believe Pfizer is more favorable than Viatris.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pfizer
1 Sell rating(s)
11 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
2.39
Viatris
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80

Pfizer has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.

Summary

Pfizer beats Viatris on 16 of the 20 factors compared between the two stocks.

Get Viatris News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VTRS vs. The Competition

MetricViatrisMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$12.01B$7.66B$5.76B$9.78B
Dividend Yield4.61%2.74%3.95%4.02%
P/E Ratio-3.5577.0530.8026.45
Price / Sales0.8245.29466.65121.64
Price / Cash2.0424.8337.7659.36
Price / Book0.7721.9910.216.69
Net Income-$634.20M$242.04M$3.26B$265.42M
7 Day Performance-3.51%1.83%3.14%3.41%
1 Month Performance11.39%0.50%4.36%1.09%
1 Year Performance-13.32%11.84%45.22%23.47%

Viatris Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VTRS
Viatris
1.9548 of 5 stars
$10.32
-1.0%
$10.40
+0.8%
-10.9%$12.01B$14.74B-3.5532,000
PFE
Pfizer
4.8835 of 5 stars
$25.07
-0.3%
$28.12
+12.2%
-13.0%$142.54B$63.63B13.3481,000Positive News
TAK
Takeda Pharmaceutical
1.7902 of 5 stars
$15.18
+1.2%
N/A-0.6%$48.31B$30.09B50.6147,455
ARGX
argenex
3.0878 of 5 stars
$661.32
+1.1%
$746.81
+12.9%
+37.0%$40.47B$2.25B33.911,599Trending News
Analyst Forecast
Analyst Revision
ONC
BeOne Medicines
1.4279 of 5 stars
$319.32
-0.6%
$330.89
+3.6%
N/A$35.00B$3.81B-184.5811,000
BNTX
BioNTech
2.892 of 5 stars
$112.55
-0.9%
$135.80
+20.7%
+18.3%$27.06B$2.98B-70.346,772Positive News
INSM
Insmed
3.7836 of 5 stars
$127.27
-0.4%
$129.57
+1.8%
+74.5%$26.90B$363.71M-22.291,271
TEVA
Teva Pharmaceutical Industries
3.4401 of 5 stars
$18.08
+1.2%
$24.71
+36.7%
-3.7%$20.74B$16.54B-113.0036,830Positive News
SMMT
Summit Therapeutics
2.2465 of 5 stars
$26.29
-1.5%
$35.00
+33.1%
+84.2%$19.53BN/A-26.03110Positive News
Analyst Forecast
Gap Down
GMAB
Genmab A/S
3.5947 of 5 stars
$23.42
+0.5%
$37.60
+60.5%
-11.2%$15.02B$3.12B11.772,682News Coverage
RDY
Dr. Reddy's Laboratories
2.9416 of 5 stars
$14.26
+0.2%
$16.95
+18.9%
-13.7%$11.90B$3.81B21.6027,811News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:VTRS) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners